Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Nov 3, 2009

Crucell Taps Calmune for Discovery Work in Infectious Diseases

  • Calmune and Crucell inked a deal focusing on research, development, production, and marketing of vaccines, proteins, and antibodies that prevent and/or treat infectious diseases. Calmune will use its SEBVI™ technology to prepare a panel of potent, high-affinity human mAbs against a predefined target.

    Crucell will have the option to exclusively license these mAbs for further evaluation and development. Calmune will receive payments from Crucell at different stages of the discovery and development process as well as a royalty on sales of products that incorporate antibodies generated by Calmune.

    SEBVI reportedly allows natural, high-affinity, fully human antibodies against microbial targets to be efficiently recovered from Epstein Barr virus-transformed memory B cells.

     



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »